Starpharma, an Australia-based biotech company, announced on Friday positive interim results from the prostate cancer cohort in its ongoing phase two trial of DEP cabazitaxel.
The company showed that 100% of evaluable patients with (Stage IV) metastatic prostate cancer have had efficacy responses, utilising one or more standard measures of disease.
DEP cabazitaxel is a patented, detergent (polysorbate-80) free, nanoparticle version of the conventional cancer drug, Jevtana that is intended to treat advanced prostate cancer. The company's interim results in prostate cancer indicated one or more efficiency signal in 100% of patients evaluated subsequent to DEP cabazitaxel treatment. Out of the total number of patients, 64% with assessable tumour lesions saw prolonged stable disease and significant decrease in tumour size for up to 36 weeks, 96% of patients with assessable Prostate Specific Antigen (PSA) tumour biomarker levels had a reduction in PSA, with more than half of these patients achieving a reduction in PSA of around 50%, 83% of patients with secondary bone disease indicated either no progression or an improvement in these lesions and 56% of patients who were assessed for three measures had responses to all three.
The company says that these positive interim results are particularly significant given all patients in this cohort had late-stage prostate cancer and had failed multiple anti-cancer treatments (including taxanes), in addition to surgeries and radiation, prior to entering the DEP cabazitaxel trial.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval